Azacitidine: all 480 studies that test it

Page 3 of 5. Open to participants first (142), then studies with results posted, then the rest; newest registration first within each.

• Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)TerminatedNCT02096042Phase 1/2Results posted
• A Study Of PF-04449913 In Japanese Patients With Select Hematologic MalignanciesCompletedNCT02038777Phase 1Results posted
• Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid MalignanciesTerminatedNCT01998035Phase 1/2Results posted
• Aza-SAHA-GBM With AutoSCT for Refractory LymphomaCompletedNCT01983969Phase 1/2Results posted
• Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMMLTerminatedNCT01957644Phase 1Results posted
• Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung CancerTerminatedNCT01935947Phase 2Results posted
• Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.CompletedNCT01928576Phase 2Results posted
• Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT01912274Phase 2Results posted
• Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT01892371Phase 1/2Results posted
• Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive ChemotherapyCompletedNCT01869114Phase 2Results posted
• Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or OlderCompletedNCT01814826Phase 1Results posted
• Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell TransplantCompletedNCT01812252Phase 2Results posted
• Addition of Vorinostat to Azacitidine in Higher Risk MDS a Phase II add-on Study in Patients With Azacitidine FailureTerminatedNCT01748240Phase 2Results posted
• Azacitidine in Patients Undergoing Matched Unrelated Stem Cell TransplantationTerminatedNCT01747499Phase 1/2Results posted
• Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid LeukemiaCompletedNCT01743859Phase 2Results posted
• Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 RiskCompletedNCT01720225Phase 2Results posted
• Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDSCompletedNCT01700673Phase 2Results posted
• Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic SyndromeCompletedNCT01599325Phase 2Results posted
• Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)TerminatedNCT01542684Phase 2Results posted
• In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and SirolimusTerminatedNCT01453140Phase 1/2Results posted
• Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDSTerminatedNCT01442714Phase 2Results posted
• A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid LeukemiaCompletedNCT01358734Phase 2Results posted
• A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic LeukemiaCompletedNCT01350947Phase 2Results posted
• Azacitidine and Entinostat in Treating Patients With Advanced Breast CancerCompletedNCT01349959Phase 2Results posted
• Azacitidine in Treating Patients With Previously Treated Advanced Non-Small Cell Lung CancerCompletedNCT01281124Phase 2Results posted
• Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic SyndromeCompletedNCT01254890Phase 1/2Results posted
• Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLLTerminatedNCT01241786Phase 2Results posted
• Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive StrategyCompletedNCT01209520Not applicableResults posted
• Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By SurgeryTerminatedNCT01207726Phase 2Results posted
• PKC412 and 5-AzacytidineCompletedNCT01202877Phase 1/2Results posted
• Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)CompletedNCT01201811Phase 4Results posted
• Azacitidine and CAPOX in Metastatic Colorectal CancerCompletedNCT01193517Phase 1/2Results posted
• An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS)CompletedNCT01186939Phase 3Results posted
• Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid LeukemiaCompletedNCT01168219Phase 2Results posted
• Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple MyelomaCompletedNCT01155583Phase 1/2Results posted
• Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone LymphomaTerminatedNCT01121757Phase 2Results posted
• Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal CancerCompletedNCT01105377Phase 2Results posted
• Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous LeukemiaCompletedNCT01093573Phase 1/2Results posted
• Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell TransplantCompletedNCT01083706Phase 2Results posted
• Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)CompletedNCT01074047Phase 3Results posted
• Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple MyelomaCompletedNCT01050790Not applicableResults posted
• 5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)CompletedNCT01038635Phase 1/2Results posted
• Azacitidine and Lenalidomide for Acute Myeloid LeukemiaCompletedNCT01016600Phase 1/2Results posted
• To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.TerminatedNCT01011283Phase 4Results posted
• Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell LymphomaCompletedNCT01004991Phase 1/2Results posted
• Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic SyndromesTerminatedNCT00997243Phase 2Results posted
• A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell CarcinomaTerminatedNCT00934440Phase 1/2Results posted
• Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AMLCompletedNCT00895934Phase 1/2Results posted
• Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)CompletedNCT00890929Phase 1/2Results posted
• Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)CompletedNCT00887068Phase 3Results posted
• Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)CompletedNCT00813124Phase 2Results posted
• Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)CompletedNCT00766116Phase 1/2Results posted
• A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast CancerCompletedNCT00748553Phase 1/2Results posted
• 5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic SyndromeCompletedNCT00721214Phase 2Results posted
• Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome Who Are Candidates For Allogeneic Hematopoietic Cell TransplantCompletedNCT00660400Not applicableResults posted
• Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaActive, not recruitingNCT00658814Phase 2Results posted
• Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal FunctionCompletedNCT00652626Phase 1Results posted
• Phase I Dose-Escalation Study Of Azacitidine In Combination With TemozolomideCompletedNCT00629343Phase 1Results posted
• Ph II Study of Azacitidine in MyelofibrosisCompletedNCT00569660Phase 2Results posted
• Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckTerminatedNCT00443261Phase 1Results posted
• PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDSCompletedNCT00439673Phase 2Results posted
• 5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic LeukemiaTerminatedNCT00413478Phase 2Results posted
• Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia (AML) in CR After Induction ChemotherapyCompletedNCT00387647Phase 2Results posted
• Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung CancerCompletedNCT00387465Phase 1/2Results posted
• A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic SyndromesCompletedNCT00384956Phase 2Results posted
• Vidaza to Restore Hormone Thx ProstateCompletedNCT00384839Phase 2Results posted
• Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) PatientsCompletedNCT00382590Phase 2Results posted
• Azacitidine in Treating Patients With MyelofibrosisTerminatedNCT00381693Phase 2Results posted
• Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic SyndromesTerminatedNCT00379912Phase 2Results posted
• Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic SyndromesCompletedNCT00352001Phase 1/2Results posted
• Phase II 5-Azacytidine Plus VPA Plus ATRACompletedNCT00326170Phase 2Results posted
• Azacitidine and Etanercept in Treating Patients With Myelodysplastic SyndromesCompletedNCT00118287Phase 1/2Results posted
• Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic SyndromesCompletedNCT00102687Phase 2Results posted
• A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional CareCompletedNCT00071799Phase 3Results posted
• Pacritinib With Aza for Upfront Myelodysplastic SyndromeWithdrawnNCT07387354Phase 1/2
• Ascorbate in Myelodysplastic SyndromeSuspendedNCT07283900Phase 2
• Pilot Study of Reduced Venetoclax ExposureActive, not recruitingNCT07163793Phase 2
• Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After TransplantationActive, not recruitingNCT07094464Phase 1
• A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid LeukemiaWithdrawnNCT06903702Phase 2
• FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid NeoplasmsActive, not recruitingNCT06858618Phase 2
• Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)SuspendedNCT06694454Phase 1/2
• Venetoclax + Azacitidine in Patients With Acute Myeloid LeukemiaActive, not recruitingNCT06668558Phase 2
• ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform TrialActive, not recruitingNCT06664879Phase 1/2
• 5-Azacytidine With Steroids for Gastrointestinal GVHD (5-AZA FOR GVHD)WithdrawnNCT06598332Early Phase 1
• Extension Study, Pilot, Compassionate Use of Azacitidine 300 mg Film Coated Tablets for Acute Myeloid Leukaemia (AML) PatientsActive, not recruitingNCT06572982Not applicable
• Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AMLSuspendedNCT06514261Phase 1
• Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS MalignanciesWithdrawnNCT06466798Phase 1
• A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive ChemotherapyActive, not recruitingNCT06456463Phase 2
• Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid LeukemiaSuspendedNCT06454409Phase 1
• Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid LeukemiaActive, not recruitingNCT06445907Phase 1
• Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeTerminatedNCT06419634Phase 1
• Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML)CompletedNCT06326697Phase 1
• Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)TerminatedNCT06158100Phase 1
• Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]TerminatedNCT06150040Phase 1/2
• Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT06068621Phase 2
• A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic LeukemiaActive, not recruitingNCT05883956Phase 3
• Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDSWithdrawnNCT05823480Phase 1
• A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)TerminatedNCT05709093Phase 3
• Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT05673057Phase 1
• Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic MalignanciesTerminatedNCT05609942Phase 1

← Azacitidine overview